{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:15:15Z","timestamp":1793837715703,"version":"4.6.1"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Karl Fazer","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"TILT Biotherapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["813453"],"award-info":[{"award-number":["813453"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["190121193"],"award-info":[{"award-number":["190121193"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["811693"],"award-info":[{"award-number":["811693"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Programme of Clinical Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HUCH Research Funds","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Sigrid Juselius Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100003127","name":"Punainen Risti Veripalvelu","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003127","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Albert Ehrnrooth","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5\/3-E2F-d24-hTNFa-IRES-hIL2, igrelimogene litadenorepvec) was developed. TILT-123 encodes two transgenes: tumor necrosis alpha (TNFa) and interleukin-2 (IL-2). TUNIMO (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04695327\">NCT04695327<\/jats:ext-link>\n                      ) was a phase I clinical trial using TILT-123 in patients with advanced solid tumors aiming to assess the safety, efficacy, and immunological effects of TILT-123. Research presented in this study evaluated the immunological effects of TILT-123 in the TUNIMO trial by using biological samples collected from the patients during the study, with an objective to leverage the findings to develop possible biomarkers of response and gain insights into possible synergistic combination treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>20 patients with advanced solid tumors were treated with TILT-123. Response to therapy was assessed with contrast-enhanced CT and fluorodeoxyglucose positron emission tomography, along with overall survival (OS) calculation. Biological samples from patients were collected in the form of blood and tumor biopsies. Collected samples were analyzed with immunohistochemistry, transcriptomics, proteomics, and flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TILT-123 induced cyclical decreases in blood lymphocyte count, and more substantial blood lymphocyte count correlated with better radiographical response and longer OS. Lymphocyte count findings were confirmed with external control dataset of 96 patients. More substantial lymphocyte count change was linked to stronger immune activation in plasma proteome after intravenous TILT-123 and the presence of TILT-123 mRNA in tumors. Regarding other assays. tumor biopsies profiled showed increased amounts of CD8+ T cells, CD4+ T cells and NK cells after intravenous TILT-123, but not after intratumoral TILT-123. Transcriptional differences were seen in tumors after intravenous therapy and intratumoral therapy, with patients benefitting therapy showing stronger downregulation of immune activation at all time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TILT-123 therapy induced accumulation of effector lymphocytes in tumors. Peripheral lymphocyte count decrease is a promising biomarker for assessing oncolytic adenovirus therapy response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010493","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:16:56Z","timestamp":1737980216000},"page":"e010493","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04695327","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04695327","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04695327","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-8612","authenticated-orcid":false,"given":"Santeri A","family":"Pakola","sequence":"first","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H A","family":"Clubb","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V","family":"Kudling","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4123-6464","authenticated-orcid":false,"given":"Mirte","family":"van der Heijden","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0606-6577","authenticated-orcid":false,"given":"Elise","family":"Jirovec","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2896","authenticated-orcid":false,"given":"Victor","family":"Arias","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriina","family":"Peltola","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-9040","authenticated-orcid":false,"given":"Tuomo","family":"Alanko","sequence":"additional","affiliation":[{"name":"Docrates Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1251","authenticated-orcid":false,"given":"Jorma","family":"Sormunen","sequence":"additional","affiliation":[{"name":"Docrates Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[{"name":"Digital Microscopy and Molecular Pathology Unit, University of Helsinki Institute for Molecular Medicine, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Taipale","sequence":"additional","affiliation":[{"name":"Health and Hospital Services, Wellbeing Services County of North Karelia \u2013 Siun sote, Joensuu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C A","family":"Quixabeira","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kistler","sequence":"additional","affiliation":[{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao M","family":"Santos","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-8530","authenticated-orcid":false,"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd, Helsinki, Finland"},{"name":"Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2025100301450642000_13.1.e010493.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0014-6"},{"key":"2025100301450642000_13.1.e010493.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w"},{"key":"2025100301450642000_13.1.e010493.3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol Ther"},{"key":"2025100301450642000_13.1.e010493.4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"2025100301450642000_13.1.e010493.5","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025100301450642000_13.1.e010493.6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad211"},{"key":"2025100301450642000_13.1.e010493.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100301450642000_13.1.e010493.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"2025100301450642000_13.1.e010493.9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ccell.2023.04.012","article-title":"RECISTv1.1 progression in oncology: Shades of gray","volume":"41","author":"Topp","year":"2023","journal-title":"Cancer Cell"},{"key":"2025100301450642000_13.1.e010493.10","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev Med Virol"},{"key":"2025100301450642000_13.1.e010493.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105219","article-title":"Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures","volume":"105","author":"Sch\u00e4fer","year":"2024","journal-title":"EBioMedicine"},{"key":"2025100301450642000_13.1.e010493.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.018"},{"key":"2025100301450642000_13.1.e010493.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.018"},{"key":"2025100301450642000_13.1.e010493.14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature New Biol"},{"key":"2025100301450642000_13.1.e010493.15","doi-asserted-by":"publisher","DOI":"10.1089\/10430340260185139"},{"key":"2025100301450642000_13.1.e010493.16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2016.67","article-title":"Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol Ther"},{"key":"2025100301450642000_13.1.e010493.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089"},{"key":"2025100301450642000_13.1.e010493.18","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100301450642000_13.1.e010493.19","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800048019"},{"key":"2025100301450642000_13.1.e010493.20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/cdli.4.4.491-492.1997","article-title":"Time to earliest peak serum antibody response to influenza vaccine in the elderly","volume":"4","author":"Gross","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"2025100301450642000_13.1.e010493.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15798-4","article-title":"Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis","volume":"7","author":"Blom","year":"2017","journal-title":"Sci Rep"},{"key":"2025100301450642000_13.1.e010493.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-021-04344-9","article-title":"CellProfiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"2025100301450642000_13.1.e010493.23","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118"},{"key":"2025100301450642000_13.1.e010493.24","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.123"},{"key":"2025100301450642000_13.1.e010493.25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy\u202f: Report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025100301450642000_13.1.e010493.26","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13680"},{"key":"2025100301450642000_13.1.e010493.27","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.161"},{"key":"2025100301450642000_13.1.e010493.28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26216"},{"key":"2025100301450642000_13.1.e010493.29","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/mt.2012.170","article-title":"Treatment of chemotherapy-refractory cancer in the advanced therapy access program","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"2025100301450642000_13.1.e010493.30","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/mt.2015.125","article-title":"Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues","volume":"23","author":"Koski","year":"2015","journal-title":"Mol Ther"},{"key":"2025100301450642000_13.1.e010493.31","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11403"},{"key":"2025100301450642000_13.1.e010493.32","doi-asserted-by":"crossref","DOI":"10.3390\/v13091876","article-title":"Lymphopenia Caused by Virus Infections and the Mechanisms Beyond","volume":"13","author":"Guo","year":"2021","journal-title":"Viruses"},{"key":"2025100301450642000_13.1.e010493.33","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jmv.25468","article-title":"Absolute lymphocyte count and human adenovirus-specific T-cell immune restoration of human adenovirus infection after kidney transplantation","volume":"91","author":"Bruminhent","year":"2019","journal-title":"J Med Virol"},{"key":"2025100301450642000_13.1.e010493.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05331.x"},{"key":"2025100301450642000_13.1.e010493.35","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"2025100301450642000_13.1.e010493.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.02.011"},{"key":"2025100301450642000_13.1.e010493.37","doi-asserted-by":"publisher","DOI":"10.1038\/mt.sj.6300120"},{"key":"2025100301450642000_13.1.e010493.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0054"},{"key":"2025100301450642000_13.1.e010493.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3642"},{"key":"2025100301450642000_13.1.e010493.40","doi-asserted-by":"publisher","DOI":"10.1089\/10430340460745829"},{"key":"2025100301450642000_13.1.e010493.41","doi-asserted-by":"crossref","DOI":"10.1038\/srep36956","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"2025100301450642000_13.1.e010493.42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103269","article-title":"The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types","volume":"65","author":"Micke","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:45:15Z","timestamp":1759481115000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-010493"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010493","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}